Center for Biotechnology and Genomic Medicine23
The Center for Biotechnology and Genomic Medicine's (CBGM) research efforts focus on two main areas: 1) discovery and validation of biomarkers for disease prediction and diagnosis, 2) pharmacomics and drug discovery for personalized medicine. CBGM is home of four internationally renowned programs in diabetes research: The Environmental Determinants of Diabetes in the Young (TEDDY), the Prospective Assessment in Newborns of Diabetes Autoimmunity (PANDA), the Diabetic Complications Consortium (DCC) and the Mouse Metabolic Phenotype Consortium (MMPC). Additional research programs include autoimmune diseases, transplantation, and cancer. These research programs are supported by an annual extramural funding of approximately $12 million.
Latest publications
- A novel subnetwork based analysis reveals shared pathways in T-cell mediated autoimmunity19Apr2016
- Lack of an association of miR-938 SNP in IDDM10 with human type 1 diabetes26Oct2012
- Reduced Serum Vitamin Dâ Binding Protein Levels Are Associated With Type 1 Diabetes26Oct2012
- Critical role of Bcl11b in suppressor function of T regulatory cells and prevention of inflammatory bowel disease26Oct2012
- The Role of Endoplasmic Reticulum Stress in Autoimmune-Mediated Beta-Cell Destruction in Type 1 Diabetes26Oct2012
All items in the repository are protected by copyright; they may be used for educational purposes with proper attribution. All other uses require the author's permission.